罗氏Roche Holdings（RHHBY）2011年年度报告「OTC」.pdf

1、7 000 917F.Hoffmann-La Roche Ltd4070 Basel,Switzerland 2012All trademarks are legally ERoche|Annual Report 2011Annual Report00_00_Roche_AR11_Front Cover_ENG.indd 127.01.2012 10:07:43was a landmark year for Roche Personalised Healthcare.This annual report highlights the progress we made in advancing

2、a strategic priority shared by the entire Roche Group.We successfully launched new tests and medicines tailored to the needs of specific patient popu-lations and made good progress in developing others that also promise to make treatment safer and more effective.At Roche we believe that medically di

3、fferentiated products benefit all healthcare stakeholders,from patients and physicians to regulators and payers.was a landmark year for Roche Personalised Healthcare.This annual report highlights the progress we made in advancing a strategic priority shared by the entire Roche Group.We successfully

4、launched new tests and medicines tailored to the needs of specific patient popu-lations and made good progress in developing others that also promise to make treatment safer and more effective.At Roche we believe that medically differentiated products benefit all healthcare stakeholders,from patient

5、s and physicians to regulators and payers.Our businessFrom precise diagnosis to targeted therapy.Together,a potent new drug and a blood test to guide its use can be a life changer for patients.Roche is a global leader in both sectors:the worlds biggest biopharmaceuticals company,the leading supplier

6、 of in vitro diagnostics and an innovator across major disease areas from cancer to virology.Our business is science-driven.We are using our exceptional research and development capabilities to develop drugs,diagnostics and drug/diagnostic combinations to address some of medicines most pressing chal